Dow Jones

40,211.72

0.53%

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XLRN

<< Anterior 2 3 4 5 6 7 8 9 10 11 12 13 14 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
16/09/2014	06:00	Business Wire	Acceleron to Host Educational Webcast Series with Clinical Thought Leaders	NASDAQ:XLRN	Acceleron Pharma Inc
12/09/2014	16:09	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XLRN	Acceleron Pharma Inc
27/08/2014	06:00	Business Wire	Acceleron Pharma to Present at Upcoming Investor Conferences in September	NASDAQ:XLRN	Acceleron Pharma Inc
20/08/2014	15:05	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:XLRN	Acceleron Pharma Inc
12/08/2014	15:12	Edgar (US Regulatory)	Amended Quarterly Report (10-q/a)	NASDAQ:XLRN	Acceleron Pharma Inc
12/08/2014	11:48	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:XLRN	Acceleron Pharma Inc
12/08/2014	06:01	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XLRN	Acceleron Pharma Inc
12/08/2014	06:00	Business Wire	Acceleron Pharma Reports Second Quarter 2014 Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
05/08/2014	06:00	Business Wire	Acceleron Pharma to Host Second Quarter 2014 Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
16/07/2014	17:54	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:XLRN	Acceleron Pharma Inc
14/07/2014	08:52	Business Wire	Acceleron Pharma Appoints Terrence C. Kearney to its Board of Directors	NASDAQ:XLRN	Acceleron Pharma Inc
10/07/2014	13:26	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:XLRN	Acceleron Pharma Inc
19/06/2014	06:00	Business Wire	Acceleron Pharma to Present at JMP Securities Healthcare Conference	NASDAQ:XLRN	Acceleron Pharma Inc
14/06/2014	14:30	Business Wire	Studienergebnisse im Rahmen der 19. Jahresversammlung der European Hematology Association (EHA) zur Evaluierung der „Activi...	NASDAQ:XLRN	Acceleron Pharma Inc
14/06/2014	12:15	Business Wire	Présentation, à l’occasion du 19ème congrès annuel de l’Association européenne d'hématologie, d’études évaluant...	NASDAQ:XLRN	Acceleron Pharma Inc
14/06/2014	02:00	Business Wire	Studies Presented at 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs in B...	NASDAQ:XLRN	Acceleron Pharma Inc
29/05/2014	06:00	Business Wire	Acceleron Pharma to Present at Upcoming Investor and Medical Conferences in June	NASDAQ:XLRN	Acceleron Pharma Inc
21/05/2014	10:00	Business Wire	Acceleron Announces New Interim Phase 2 Data on Sotatercept & ACE-536 to be Reported at Three Oral Presentations at the 19th ...	NASDAQ:XLRN	Acceleron Pharma Inc
15/05/2014	06:30	Business Wire	Acceleron Pharma Reports First Quarter 2014 Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
14/05/2014	16:00	Business Wire	Acceleron to Report New Encouraging Interim Clinical Data from Phase 2 Trial of Dalantercept in Renal Cell Carcinoma at the 5...	NASDAQ:XLRN	Acceleron Pharma Inc
13/05/2014	16:29	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:XLRN	Acceleron Pharma Inc
12/05/2014	10:26	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:XLRN	Acceleron Pharma Inc
12/05/2014	06:00	Business Wire	Acceleron to Present at 2014 UBS Global Healthcare Conference	NASDAQ:XLRN	Acceleron Pharma Inc
08/05/2014	06:00	Business Wire	Acceleron Pharma to Host First Quarter 2014 Financial Results Conference Call and Webcast on May 15, 2014	NASDAQ:XLRN	Acceleron Pharma Inc
02/05/2014	15:24	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:XLRN	Acceleron Pharma Inc
30/04/2014	16:25	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:XLRN	Acceleron Pharma Inc
23/04/2014	15:30	Business Wire	Acceleron & Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Pa...	NASDAQ:XLRN	Acceleron Pharma Inc
11/04/2014	07:00	PR Newswire (US)	FDA Recommendations, Study Publications, Recognitions, Agreements, and Acquisitions - Analyst Notes on MannKind, Acceleron, S...	NASDAQ:XLRN	Acceleron Pharma Inc
02/04/2014	09:54	Dow Jones News	Celgene Agrees to Acquire 1.1 Million Acceleron Pharma Shares	NASDAQ:XLRN	Acceleron Pharma Inc
24/03/2014	06:30	Business Wire	Acceleron, Celgene & Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept & ACE-536 Therapeutic ...	NASDAQ:XLRN	Acceleron Pharma Inc